Epoetin theta
As of the edition of 20 October 2026, Epoetin theta is a protein: marketed, first approved in 2009 (EU); acts on EPOR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Protein
- Brand name
- Biopoin
- First approved
- 23 October 2009 (EU)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Ratiopharm; 2 holders in all
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| EPOR | Erythropoietin receptor | P19235 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Teva | Applicant | 2009 to now |
| Ratiopharm | Later holder | 2009 to now |